210 related articles for article (PubMed ID: 37686122)
61. Radon Exposure-induced Genetic Variations in Lung Cancers among Never Smokers.
Choi JR; Koh SB; Kim HR; Lee H; Kang DR
J Korean Med Sci; 2018 Jul; 33(29):e207. PubMed ID: 30008631
[TBL] [Abstract][Full Text] [Related]
62. Investigation of EGFR and ALK mutation frequency and treatment results in advanced non-small cell lung cancer.
Komurcuoglu B; Karakurt G; Kaya OO; Diniz G; Kırbıyık O; Evkan A; Yalnız E
J Cancer Res Ther; 2023 Apr; 19(Supplement):S183-S190. PubMed ID: 37147996
[TBL] [Abstract][Full Text] [Related]
63. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
Casaluce F; Sgambato A; Maione P; Rossi A; Ferrara C; Napolitano A; Palazzolo G; Ciardiello F; Gridelli C
Target Oncol; 2013 Mar; 8(1):55-67. PubMed ID: 23325296
[TBL] [Abstract][Full Text] [Related]
64. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
65. Distinct immune microenvironment of lung adenocarcinoma in never-smokers from smokers.
Luo W; Zeng Z; Jin Y; Yang L; Fan T; Wang Z; Pan Y; Yang Y; Yao M; Li Y; Xiao X; Wang G; Wang C; Chang S; Che G; Zhang L; Li Y; Peng Y; Li W
Cell Rep Med; 2023 Jun; 4(6):101078. PubMed ID: 37301197
[TBL] [Abstract][Full Text] [Related]
66. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
[TBL] [Abstract][Full Text] [Related]
67. Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients.
Wang C; Yin R; Dai J; Gu Y; Cui S; Ma H; Zhang Z; Huang J; Qin N; Jiang T; Geng L; Zhu M; Pu Z; Du F; Wang Y; Yang J; Chen L; Wang Q; Jiang Y; Dong L; Yao Y; Jin G; Hu Z; Jiang L; Xu L; Shen H
Nat Commun; 2018 May; 9(1):2054. PubMed ID: 29799009
[TBL] [Abstract][Full Text] [Related]
68. Lung cancer in never smokers--a review.
Couraud S; Zalcman G; Milleron B; Morin F; Souquet PJ
Eur J Cancer; 2012 Jun; 48(9):1299-311. PubMed ID: 22464348
[TBL] [Abstract][Full Text] [Related]
69.
Dong YU; Ren W; Qi J; Jin BO; Li Y; Tao H; Xu R; Li Y; Zhang Q; Han B
Oncol Lett; 2016 Apr; 11(4):2371-2378. PubMed ID: 27073482
[TBL] [Abstract][Full Text] [Related]
70. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G
Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
[TBL] [Abstract][Full Text] [Related]
71. Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
Ou SH
Postgrad Med J; 2014 Apr; 90(1062):228-35. PubMed ID: 24643262
[TBL] [Abstract][Full Text] [Related]
72. Tumor response to radiotherapy and expression of epidermal growth factor receptor mutation and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement in patients with non-small cell lung cancer.
Nagi NMS; Khair YAM; Bakari KH; Nagi MN; Mghanga FP
J Egypt Natl Canc Inst; 2022 Jul; 34(1):29. PubMed ID: 35811311
[TBL] [Abstract][Full Text] [Related]
73. Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy.
Singh SS; Dahal A; Shrestha L; Jois SD
Curr Med Chem; 2020; 27(32):5274-5316. PubMed ID: 30854949
[TBL] [Abstract][Full Text] [Related]
74. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.
Rizzo S; Petrella F; Buscarino V; De Maria F; Raimondi S; Barberis M; Fumagalli C; Spitaleri G; Rampinelli C; De Marinis F; Spaggiari L; Bellomi M
Eur Radiol; 2016 Jan; 26(1):32-42. PubMed ID: 25956936
[TBL] [Abstract][Full Text] [Related]
75. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.
Chamorro DF; Cardona AF; Rodríguez J; Ruiz-Patiño A; Arrieta O; Moreno-Pérez DA; Rojas L; Zatarain-Barrón ZL; Ardila DV; Viola L; Recondo G; Blaquier JB; Martín C; Raez L; Samtani S; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Archila P; Bermudez M; Gamez T; Russo A; Malapelle U; de Miguel Perez D; de Lima VCC; Freitas H; Saldahna E; Rolfo C; Rosell R;
Target Oncol; 2023 May; 18(3):425-440. PubMed ID: 37017806
[TBL] [Abstract][Full Text] [Related]
76. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.
Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS
Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993
[TBL] [Abstract][Full Text] [Related]
77. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
78. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
79. Current status of research and treatment for non-small cell lung cancer in never-smoking females.
Saito S; Espinoza-Mercado F; Liu H; Sata N; Cui X; Soukiasian HJ
Cancer Biol Ther; 2017 Jun; 18(6):359-368. PubMed ID: 28494184
[TBL] [Abstract][Full Text] [Related]
80. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.
Wu YC; Chang IC; Wang CL; Chen TD; Chen YT; Liu HP; Chu Y; Chiu YT; Wu TH; Chou LH; Chen YR; Huang SF
PLoS One; 2013; 8(8):e70839. PubMed ID: 23951022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
